Clinical trials
Glioblastoma, IDH-wildtype clinical trials
Below are recruiting glioblastoma, idh-wildtype clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07708961RecruitingPhase 2
Temozolomide with or without WSD0922-FU for EGFR-mutant glioblastoma
This trial tests whether adding a new drug, WSD0922-FU, to standard chemotherapy (temozolomide) works better than temozolomide alone for a specific type of glioblastoma that has an EGFR mutation. It is for patients who have completed radiation and temozolomide together but haven't started maintenance temozolomide yet.
Scottsdale, ArizonaAges 18 years+ - NCT05326334Recruiting
Study gut microbiome in new glioblastoma patients
This trial studies how changes in gut bacteria (gut microbiome) relate to outcomes in people with newly diagnosed glioblastoma receiving standard chemo-radiation. It may help doctors learn which gut-bacteria patterns go along with better or worse results during treatment.
Ottawa, OntarioAges 18 years+ - NCT06146725Recruiting
Resection vs. biopsy in high-grade glioma patients
This study compares whether having surgery to remove as much of the tumor as possible (resection) or just taking a small sample (biopsy) leads to better outcomes for people with a fast-growing brain tumor (high-grade glioma). The goal is to help guide treatment decisions.
San Francisco, CaliforniaAges 18–90 - NCT06146738Recruiting
Palliative care vs. surgery for high-grade glioma patients
This study compares receiving palliative care (supportive treatments) versus surgery (removing the tumor) for people with a high-grade glioma, a fast-growing brain tumor. The goal is to find out which approach improves quality of life and survival.
San Francisco, CaliforniaAges 18–90 - NCT06160596Recruiting
Understanding long-term cancer survival in hard-to-treat tumors
This study looks at why some people with hard-to-treat cancers live much longer than expected. It collects tumor samples to search for clues that might help future patients.
VillejuifAges 18 years+ - NCT06118723Recruiting
Supramaximal vs maximal surgery for brain tumors
This trial compares removing as much tumor as safely possible (supramaximal resection) with standard maximal resection in people with high-grade glioma (an aggressive brain tumor). The goal is to see if more extensive removal improves survival and quality of life.
San Francisco, CaliforniaAges 18–90 - NCT06273176Recruiting
Surgery with or without brain mapping for recurrent glioblastoma
This study is testing whether using a special brain-mapping technique during surgery helps people with recurrent glioblastoma. It compares standard surgery to surgery with mapping to see if it leads to better outcomes for tumors near important brain areas.
San Francisco, CaliforniaAges Up to 90 years - NCT06283927Recruiting
Surgery vs. medical care for recurrent glioblastoma
This trial compares surgery to the best non-surgical treatment for people whose glioblastoma has come back. The goal is to see which approach helps people live longer with a better quality of life.
San Francisco, CaliforniaAges 18–90 - NCT06327451RecruitingPhase 2
Atorvastatin plus temozolomide for EGFR-positive glioblastoma
This trial tests whether adding the cholesterol drug atorvastatin to the standard chemotherapy temozolomide improves outcomes for people with a specific type of glioblastoma (brain cancer) that is positive for the EGFR protein. It aims to find a more effective treatment for this aggressive tumor.
TianjinAges 18–60 - NCT06418113RecruitingPhase 1
Radiation and chemo before surgery for glioblastoma
This trial tests giving radiation and chemotherapy before surgery for glioblastoma. It aims to see if this approach is safe and may help improve outcomes for patients whose tumor can be completely removed.
MadridAges 18–75 - NCT07668869Recruiting
Electric fields with targeted radiation vs. alone for recurrent brain cancer
This trial tests whether adding a precise, MRI-guided radiation treatment to tumor-treating electric fields (TTFields) can help people with recurrent glioblastoma. You may qualify if your tumor has come back 1 to 3 times after standard therapy and you haven't had certain prior treatments.
BydgoszczAges 18 years+ - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT07520214Enrolling by invitationEarly Phase 1
Cancer vaccine to prevent glioblastoma recurrence
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07468136RecruitingPhase 1/Phase 2
Retifanlimab with or without DFMO for progressive high-grade gliomas
This study tests a combination of two drugs—retifanlimab (an immunotherapy that helps your immune system fight cancer) and DFMO (a medicine that may stop tumor growth)—in people with high-grade brain tumors that are growing. Participants will receive these treatments before and after their planned surgery.
Rochester, MinnesotaAges 18 years+ - NCT07452458RecruitingPhase 3
Pulsed vs standard radiation for newly diagnosed glioblastoma
This trial tests a new way of giving radiation therapy (pulsed) compared to standard radiation for people with a specific type of glioblastoma (IDH wildtype, MGMT unmethylated). The goal is to see if the pulsed approach helps with thinking and memory while still treating the tumor.
Irvine, CaliforniaAges 18 years+ - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT05941234Recruiting
Studying stem cells and blood patterns in glioblastoma
This study analyzes tissue and health-related biological data from people with glioblastoma to learn what’s happening in the tumor. The results may help improve future ways to understand and treat glioblastoma using advanced computer analysis.
RomeAges 18 years+ - NCT07301268RecruitingPhase 2
GI-102 with or without pembrolizumab before brain surgery
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
Rochester, MinnesotaAges 18 years+ - NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
Basking Ridge, New JerseyAges 18 years+ - NCT07111195Recruiting
Using ONCOhabitats to plan brain tumor surgery
This study tests a computer tool called ONCOhabitats that helps doctors plan surgery and treatment for a type of aggressive brain tumor called glioblastoma. By using your MRI scans, the tool may help guide the surgeon to remove as much tumor as possible while sparing healthy brain tissue.
AlicanteAges 18 years+ - NCT07089641RecruitingPhase 1
Study of ERAS-801 for recurrent or newly diagnosed glioblastoma with EGFR changes
This trial tests an experimental drug called ERAS-801 for people with a type of brain cancer called glioblastoma or gliosarcoma that has a specific genetic change (EGFR amplification or mutation). The study has two groups: one for people whose tumor has come back after treatment, and another for older adults (70+) who are newly diagnosed. The drug targets the EGFR pathway, which may help slow tumor growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07091864Recruiting
Glucose monitoring for brain tumor patients
This study tests whether using a continuous glucose monitor (a small device that tracks blood sugar levels) can help manage high blood sugar in people newly diagnosed with glioblastoma, a type of brain cancer. It aims to see if this monitoring can improve overall health during treatment.
Phoenix, ArizonaAges 18 years+ - NCT05879367RecruitingPhase 1
Eflornithine plus temozolomide for newly diagnosed brain cancer
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
Birmingham, AlabamaAges 18 years+ - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Duarte, CaliforniaAges 18 years+
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Glioblastoma, IDH-wildtype trials by city
Studies with a site in or near these metro areas.
Glioblastoma, IDH-wildtype trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for glioblastoma, idh-wildtype?
- Yes. Clin2 currently lists 40 recruiting glioblastoma, idh-wildtype studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioblastoma, idh-wildtype trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioblastoma, idh-wildtype trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.